Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial. The Spectra trial evaluates 4D-150 in patients with ...
Mapping tumor cell protein networks in vivo will be critical for realizing the promise of patient-tailored molecular therapy. Cancer can be defined as a dysregulation or hyperactivity in the network ...
Researchers at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) report new insights into how cone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results